NCT05383742
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
At risk: Primary completion moved at least 1 year 5 months later.
See at-risk trials from National Institute of Allergy and Infectious Diseases (NIAID)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 18 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Apr 30, 2028 to Oct 1, 2029
- Eligibility criteria expanded, about 24 words
- Study completion pushed from Sep 15, 2029 to Mar 5, 2030
- Study sites revised (18)
- Minor Site contacts updated at 1 of 18 sitesv19
- Notable Trial status: Suspended to Recruiting
- Site details revised at 18 of 18 sites
- Minor Primary completion date: Dec 1, 2027 to Apr 30, 2028
- Study completion date: May 15, 2028 to Sep 15, 2029
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Temporarily Closed (Paused) to Accrual
- Site details revised at 18 of 18 sites
Show 12 earlier versionsHide 12 earlier versions
Notable Primary completion date: May 10, 2027 to Dec 1, 2027v15 Show 5 more changesShow less
- Eligibility criteria shortened, about 16 words
- Study sites: 16 to 18
- Study completion date: May 10, 2027 to May 15, 2028
- Secondary endpoints: 30 to 21
- Study description expanded, about 7 words
- Minor Site details revised at 1 of 16 sitesv14
- Notable Primary and study completion dates: Aug 2, 2026 to May 10, 2027v13
- Minor Study sites: 15 to 16v12
- Minor Study sites: 10 to 15v11
- Minor Site details revised at 1 of 10 sitesv10
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 2, 2024 to Dec 7, 2023
- Study sites revised (10)
- Notable Start date: Oct 31, 2023 to Jan 2, 2024v8
- Notable Start date: Jun 1, 2023 to Oct 31, 2023v7
- Notable Start date: Mar 1, 2023 to Jun 1, 2023v6
- Notable Start date: Oct 14, 2022 to Mar 1, 2023v4
- Notable Start date: Aug 15, 2022 to Oct 14, 2022v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 2 weeks, followed by RIF 35 mg/kg + INH 10 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 6 weeks, and then RIF 35 mg/kg and INH 10 mg/kg for 16 weeks, for a total of 24 weeks of study treatment.
WHO SOC: RIF 10 mg/kg + INH 5 mg/kg + ethambutol (EMB) 20 mg/kg + PZA 25 mg/kg for 8 weeks, followed by RIF 10 mg/kg and INH 5 mg/kg for 28 weeks, for a total of 36 weeks of study treatment. Up to 15 mg/kg or a maximum of 900 mg daily of oral RIF will be permitted in this arm at clinician's discretion.
Drugs: Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD), Pyrazinamide (PZA), ethambutol (EMB), Rifampicin, Isoniazid
Sites
18 sites in 12 countries
Thailand 3, Brazil 2, Kenya 2, Peru 2, South Africa 2, India 1, Malawi 1, Mexico 1, Philippines 1, Tanzania 1, Vietnam 1, Zimbabwe 1